How I Approach CML TKI Discontinuation
Description
Upon viewing this session, you will be able to:
• Review the data from clinical trials that have evaluated the feasibility of discontinuation of TKI therapy in patients with chronic phase CML.
• Identify the criteria required to attempt discontinuation of TKI therapy, and the prognostic factors associated with recurrence after stopping TKI therapy.
• Review the data from clinical trials that have evaluated the feasibility of discontinuation of TKI therapy in patients with chronic phase CML.
• Identify the criteria required to attempt discontinuation of TKI therapy, and the prognostic factors associated with recurrence after stopping TKI therapy.
Presenters
- Neil Shah, MD, PhD, University of Califronia – San Francisco
Pricing
| Member Type | Price |
|---|---|
| List Price | $30.00 |
| Active, International, Emeritus, and Honorary Members | $20.00 |
| Associate, International Associate, Student, and Resident Members | $20.00 |
ASH Meeting on Hematologic Malignancies
Hear the latest developments in clinical care, and get answers to your most challenging patient care questions.
Learn more
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
Copyright © 2021 by American Society of Hematology